NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 348 filers reported holding NEKTAR THERAPEUTICS in Q4 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $51,000 | -93.6% | 13,500 | -90.9% | 0.00% | – |
| Q1 2022 | $801,000 | -1.2% | 148,500 | +228.6% | 0.00% | – |
| Q3 2021 | $811,000 | +51.9% | 45,188 | +45.3% | 0.00% | – |
| Q2 2021 | $534,000 | +1383.3% | 31,100 | +2787.7% | 0.00% | – |
| Q1 2019 | $36,000 | -99.3% | 1,077 | -99.3% | 0.00% | -100.0% |
| Q4 2018 | $5,114,000 | -89.4% | 155,548 | -80.3% | 0.01% | -87.9% |
| Q3 2018 | $48,149,000 | +1.0% | 789,855 | -19.1% | 0.06% | -14.7% |
| Q2 2018 | $47,679,000 | +2383850.0% | 976,456 | +5743758.8% | 0.07% | – |
| Q1 2018 | $2,000 | -100.0% | 17 | -100.0% | 0.00% | -100.0% |
| Q4 2017 | $4,034,000 | – | 67,554 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |